Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies
by on Tuesday, September 11th, 2012 | No Comments
Condition: Solid Tumor
Interventions: Drug: Topotecan; Drug: Sorafenib
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Pediatric Cancer Foundation; Bayer
Not yet recruiting – verified September 2012
The rest is here: Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies